KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Current Leases (2019 - 2026)

Pacira BioSciences has reported Current Leases over the past 8 years, most recently at $9.8 million for Q1 2026.

  • For Q1 2026, Current Leases rose 4.39% year-over-year to $9.8 million; the TTM value through Mar 2026 reached $9.8 million, up 4.39%, while the annual FY2025 figure was $9.8 million, 10.71% up from the prior year.
  • Current Leases for Q1 2026 was $9.8 million at Pacira BioSciences, roughly flat from $9.8 million in the prior quarter.
  • Over five years, Current Leases peaked at $9.8 million in Q4 2025 and troughed at $8.0 million in Q1 2022.
  • A 5-year average of $9.0 million and a median of $9.0 million in 2024 define the central range for Current Leases.
  • Biggest five-year swings in Current Leases: soared 45.7% in 2022 and later dropped 3.51% in 2023.
  • Year by year, Current Leases stood at $9.1 million in 2022, then decreased by 3.51% to $8.8 million in 2023, then grew by 0.98% to $8.9 million in 2024, then increased by 10.71% to $9.8 million in 2025, then decreased by 0.21% to $9.8 million in 2026.
  • Business Quant data shows Current Leases for PCRX at $9.8 million in Q1 2026, $9.8 million in Q4 2025, and $9.7 million in Q3 2025.